Oruka Therapeutics (NASDAQ:ORKA) Sees Large Volume Increase – Should You Buy?

Posted by Brian Himes on Jul 17th, 2026

Oruka Therapeutics, Inc. (NASDAQ:ORKA – Get Free Report) shares saw unusually-high trading volume on Friday . Approximately 1,210,388 shares changed hands during mid-day trading, an increase of 3% from the previous session’s volume of 1,177,664 shares.The stock last traded at $87.8740 and had previously closed at $83.04.

Analyst Ratings Changes

Several brokerages have recently issued reports on ORKA. UBS Group boosted their price objective on Oruka Therapeutics from $100.00 to $130.00 and gave the stock a “buy” rating in a research report on Wednesday, July 1st. BTIG Research restated a “buy” rating and issued a $151.00 target price on shares of Oruka Therapeutics in a research report on Monday. Guggenheim set a $200.00 target price on Oruka Therapeutics and gave the company a “buy” rating in a research note on Monday, April 27th. Wall Street Zen lowered Oruka Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, June 13th. Finally, Wedbush set a $165.00 price target on Oruka Therapeutics in a research report on Monday, April 27th. Ten analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $134.30.

Check Out Our Latest Analysis on Oruka Therapeutics

Oruka Therapeutics Stock Performance

The stock has a market cap of $5.48 billion, a price-to-earnings ratio of -46.68 and a beta of -0.35. The company’s 50 day simple moving average is $71.95 and its 200 day simple moving average is $53.01.

Oruka Therapeutics (NASDAQ:ORKA – Get Free Report) last issued its quarterly earnings results on Wednesday, May 13th. The company reported ($0.48) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.04. Sell-side analysts predict that Oruka Therapeutics, Inc. will post -2.06 EPS for the current year.

Insider Transactions at Oruka Therapeutics

In other Oruka Therapeutics news, Director Carl Dambkowski sold 12,583 shares of the stock in a transaction on Friday, June 12th. The stock was sold at an average price of $70.11, for a total transaction of $882,194.13. Following the completion of the transaction, the director directly owned 38,743 shares of the company’s stock, valued at approximately $2,716,271.73. This trade represents a 24.52% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Lawrence Otto Klein sold 1,729 shares of the stock in a transaction on Monday, June 15th. The shares were sold at an average price of $69.69, for a total value of $120,494.01. Following the transaction, the chief executive officer directly owned 925,580 shares of the company’s stock, valued at approximately $64,503,670.20. The trade was a 0.19% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders have sold 188,406 shares of company stock valued at $12,019,683. 23.49% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Legal & General Group Plc bought a new position in Oruka Therapeutics during the second quarter valued at about $28,000. BNP Paribas Financial Markets raised its position in Oruka Therapeutics by 464.0% in the second quarter. BNP Paribas Financial Markets now owns 2,803 shares of the company’s stock worth $31,000 after acquiring an additional 2,306 shares in the last quarter. Royal Bank of Canada lifted its holdings in Oruka Therapeutics by 47.2% in the 4th quarter. Royal Bank of Canada now owns 1,139 shares of the company’s stock valued at $34,000 after acquiring an additional 365 shares during the last quarter. Los Angeles Capital Management LLC acquired a new stake in Oruka Therapeutics in the 4th quarter valued at about $37,000. Finally, PNC Financial Services Group Inc. bought a new position in shares of Oruka Therapeutics during the 3rd quarter valued at about $39,000. Institutional investors own 56.44% of the company’s stock.

About Oruka Therapeutics

(Get Free Report)

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.